LIFE bioCEEd

11/09/2025

Czech Biotech patent sold for hundreds of millions

Investor Michal Zahradníček, co-founder of LIFE BioCEEd, has sold a unique European patent for processing umbilical cord blood to the German biotech company Vita 34 for hundreds of millions of crowns.

This transaction is not only a business success but also a strong signal of the global potential of Czech science and innovation. The patent enables broader use of stem cells in regenerative medicine and offers hope for the treatment of serious diseases, from leukemia to cerebral palsy and autism.

Read the full article on Seznam Zprávy: https://www.seznamzpravy.cz/clanek/ekonomika-firmy-uveril-vyzkumu-krve-kteremu-hrozil-konec-patent-prodal-za-stamiliony-277971

15/10/2026

LIFE bioCEEd Featured in Wired Czech Republic – Only Innovation Gives a Nation Wealth and Independence

Our co-founder Michal Zahradníček spoke with Wired Czech Republic about why excellent Czech and European science so rarely turns into new technologies and globally successful companies, and what needs to change for research results to make their way from the laboratory into practice.

23/09/2026

LIFE bioCEEd Featured on The Forbes Show – Investing Where Innovation Can Ease Suffering

Our co-founder Michal Zahradníček was a guest on the latest episode of The Forbes Show, a podcast by Forbes Czech Republic. He spoke about his path into biotechnology, regenerative medicine, artificial organs, and also about investments that did not work out.

07/07/2026

LIFE bioCEEd Invests into Potentially First-in-Class microRNA-Targeting Therapy for ALS from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

LIFE bioCEEd invests into a potentially first-in-class therapeutic platform for Amyotrophic Lateral Sclerosis (ALS) from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, Italy, one of Europe's foremost academic medical centres. The platform, developed in the Neural Stem Cell Laboratory of Professor Stefania Corti, is based on a novel anti-miR morpholino antisense oligonucleotide (ASO) that targets the microRNA-129-1 (miR-129-1) pathway, with the aim of achieving genuine disease modification across a broad population of ALS patients, regardless of their genetic background. The agreement was signed on 1 July 2026 and expands LIFE bioCEEd's growing portfolio of innovative biomedical programmes across Europe.